H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 97 Citations 50,330 769 World Ranking 777 National Ranking 5
Medicine D-index 132 Citations 63,195 913 World Ranking 940 National Ranking 5

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Cancer

His main research concerns Immunology, Immunoglobulin E, Internal medicine, Mast cell and Systemic mastocytosis. In most of his Immunology studies, his work intersects topics such as Molecular biology. He has included themes like Allergen, Hypoallergenic, Recombinant DNA and Histamine in his Immunoglobulin E study.

Peter Valent interconnects Endocrinology, Surgery and Oncology in the investigation of issues within Internal medicine. His study looks at the intersection of Mast cell and topics like Interleukin 33 with Interleukin 5. His studies in Systemic mastocytosis integrate themes in fields like Dermatology and Urticaria pigmentosa.

His most cited work include:

  • Revised International Prognostic Scoring System for Myelodysplastic Syndromes (1564 citations)
  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia (1380 citations)
  • Diagnostic criteria and classification of mastocytosis: a consensus proposal (853 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Immunology, Internal medicine, Cancer research, Systemic mastocytosis and Myeloid leukemia. His research in Immunoglobulin E, Mast cell, Allergen, Allergy and Myeloid are components of Immunology. Peter Valent combines subjects such as Molecular biology and Histamine with his study of Immunoglobulin E.

His studies deal with areas such as Gastroenterology, Endocrinology and Oncology as well as Internal medicine. His work carried out in the field of Cancer research brings together such families of science as Tyrosine kinase, ABL, Leukemia and Stem cell. Peter Valent is conducting research in Bone marrow and Disease as part of his Systemic mastocytosis study.

He most often published in these fields:

  • Immunology (39.25%)
  • Internal medicine (24.83%)
  • Cancer research (23.72%)

What were the highlights of his more recent work (between 2016-2021)?

  • Cancer research (23.72%)
  • Internal medicine (24.83%)
  • Systemic mastocytosis (20.82%)

In recent papers he was focusing on the following fields of study:

Peter Valent focuses on Cancer research, Internal medicine, Systemic mastocytosis, Leukemia and Myeloid leukemia. The Cancer research study which covers Haematopoiesis that intersects with STAT5. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology.

His study looks at the relationship between Systemic mastocytosis and fields such as Tryptase, as well as how they intersect with chemical problems. Peter Valent has researched Myeloid leukemia in several fields, including Myeloid and Tyrosine-kinase inhibitor. His Mast cell study improves the overall literature in Immunology.

Between 2016 and 2021, his most popular works were:

  • Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts (230 citations)
  • BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. (118 citations)
  • Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future (106 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Gene
  • Cancer

His scientific interests lie mostly in Cancer research, Leukemia, Systemic mastocytosis, Immunology and Myeloid leukemia. His Cancer research research includes elements of Cell culture, STAT5, Haematopoiesis, Stem cell and Lymphoma. His Leukemia study combines topics in areas such as Synthetic lethality, DNA repair, Myeloid, ABL and Tyrosine-kinase inhibitor.

His Systemic mastocytosis research also covers Internal medicine, Mast cell and Disease studies. Peter Valent combines topics linked to Angiogenesis with his work on Immunology. Peter Valent has included themes like Tyrosine kinase, Oncology and CD38 in his Myeloid leukemia study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)

2252 Citations

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Johannes Zuber;Junwei Shi;Junwei Shi;Eric Wang;Amy R. Rappaport;Amy R. Rappaport.
Nature (2011)

1699 Citations

Diagnostic criteria and classification of mastocytosis: a consensus proposal

Peter Valent;Hans P. Horny;Luis Escribano;B. Jack Longley.
Leukemia Research (2001)

1176 Citations

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Detlef Haase;Ulrich Germing;Julie Schanz;Michael Pfeilstöcker.
Blood (2007)

924 Citations

Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals

Rudolf Valenta;Michael Duchene;Karin Pettenburger;Christian Sillaber.
Science (1991)

891 Citations

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.

P. Valent;C. Akin;L. Escribano;M. Födinger.
European Journal of Clinical Investigation (2007)

774 Citations

Profilins constitute a novel family of functional plant pan-allergens.

R Valenta;M Duchene;C Ebner;P Valent.
Journal of Experimental Medicine (1992)

678 Citations

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

Peter Valent;Hans-Peter Horny;John M. Bennett;Christa Fonatsch.
Leukemia Research (2007)

673 Citations

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix;Oliver Hantschel;Gerhard Dürnberger;Lily L. Remsing Rix.
Blood (2007)

670 Citations

Cancer stem cell definitions and terminology: the devil is in the details

Peter Valent;Dominique Bonnet;Ruggero De Maria;Tsvee Lapidot.
Nature Reviews Cancer (2012)

653 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Peter Valent

Rudolf Valenta

Rudolf Valenta

Medical University of Vienna

Publications: 405

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 150

Guillermo Garcia-Manero

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

Publications: 118

Ulrich Germing

Ulrich Germing

Heinrich Heine University Düsseldorf

Publications: 115

Mikkael A. Sekeres

Mikkael A. Sekeres

Cleveland Clinic

Publications: 104

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 104

Pierre Fenaux

Pierre Fenaux

Université Paris Cité

Publications: 102

Ayalew Tefferi

Ayalew Tefferi

Mayo Clinic

Publications: 102

Susanne Vrtala

Susanne Vrtala

Medical University of Vienna

Publications: 100

Alan F. List

Alan F. List

Precision BioSciences

Publications: 96

James E. Bradner

James E. Bradner

Harvard University

Publications: 96

Dean D. Metcalfe

Dean D. Metcalfe

National Institutes of Health

Publications: 92

Fatima Ferreira

Fatima Ferreira

University of Salzburg

Publications: 92

David P. Steensma

David P. Steensma

Harvard University

Publications: 91

Olivier Hermine

Olivier Hermine

Université Paris Cité

Publications: 90

Alberto Orfao

Alberto Orfao

University of Salamanca

Publications: 87

Something went wrong. Please try again later.